PRKN

PRKN
Emw · CC BY-SA 3.0 · source
Name	Parkin RBR E3 ubiquitin protein ligase
Uniprot	O60260
Organism	Human
Length	465 aa

PRKN PRKN is a human gene encoding an E3 ubiquitin ligase involved in intracellular protein quality control, mitophagy, and neuronal maintenance. It has been studied across clinical genetics, cell biology, and neuroscience in relation to early-onset movement disorders and neurodegeneration. Research on PRKN intersects with teams and institutions such as Howard Hughes Medical Institute, National Institutes of Health, Massachusetts Institute of Technology, and consortia involved in large-scale genomics like 1000 Genomes Project and Genome Project-Write.

Introduction

PRKN was first characterized in linkage studies involving pedigrees from research groups at University of Lund, University of Tokyo, and collaborative networks including Wellcome Trust. The gene attracted attention after associations with autosomal recessive juvenile parkinsonism reported by laboratories at National Institute of Neurological Disorders and Stroke and clinical centers such as Mayo Clinic and Johns Hopkins Hospital. Work linking PRKN to mitochondrial quality control drew on conceptual frameworks from investigators at Salk Institute and Max Planck Society.

Gene and protein structure

The PRKN locus maps to human chromosome 6 and encodes a 465–amino acid protein containing an N-terminal ubiquitin-like (Ubl) domain and a series of RING-between-RING (RBR) domains. Structural biology studies from groups at European Molecular Biology Laboratory and Cold Spring Harbor Laboratory used X-ray crystallography and cryo-EM to resolve conformations involving the RING0, RING1, and RING2 motifs and the In-Between-RING (IBR) region. Sequence comparisons leveraging resources like Ensembl and GenBank reveal conservation across metazoans and orthology to proteins studied at University of Cambridge and University of California, Berkeley. Protein interactions with E2 conjugating enzymes and substrates have been characterized in biochemical assays at facilities including Stanford University and Massachusetts General Hospital.

Function and biological role

PRKN acts as an E3 ubiquitin ligase that tags proteins and organelles for proteasomal degradation or autophagic clearance. Cellular studies from laboratories at University of Oxford and Harvard Medical School demonstrated roles in mitophagy alongside PINK1, coordinating with pathways studied at Imperial College London and University of California, San Francisco. In neuronal systems investigated at Rockefeller University and Columbia University Irving Medical Center, PRKN contributes to synaptic integrity and mitochondrial dynamics. Model organism research in labs affiliated with University of Geneva and University of Toronto used Drosophila and zebrafish to show effects on locomotor behavior and lifespan.

Pathogenic variants and disease associations

Biallelic loss-of-function variants in PRKN are a leading cause of autosomal recessive early-onset parkinsonism identified in cohorts assembled by clinics such as Mayo Clinic and research consortia including European Parkinson's Disease Association. Pathogenic alterations include exon rearrangements, point mutations, and copy-number variants detected in studies from NIH National Human Genome Research Institute and diagnostic centers at Karolinska Institutet. Clinical phenotypes overlap with syndromes catalogued by groups at Mount Sinai Health System and registries like Global Parkinson’s Genetics Program and include juvenile-onset tremor, dystonia, and slow progression compared with sporadic forms described by teams at University College London Hospital.

Diagnosis and genetic testing

Diagnostic workflows employ sequencing and structural assays used by laboratories at American College of Medical Genetics and Genomics accredited centers, including multiplex ligation-dependent probe amplification (MLPA) and next-generation sequencing panels developed by companies such as Illumina and diagnostic laboratories at Quest Diagnostics. Clinical geneticists at institutions like Cleveland Clinic rely on variant interpretation frameworks established by professional societies including European Society of Human Genetics and databases curated by ClinVar and Human Gene Mutation Database. Genetic counseling is provided following guidelines from organizations such as American Society of Human Genetics.

Molecular mechanisms and models

Mechanistic work links PRKN activation to mitochondrial depolarization, PINK1 stabilization, ubiquitin phosphorylation, and recruitment of autophagy receptors—a pathway elucidated in landmark papers from groups at University of Dundee and University of Oxford. Disease models include knockout mice generated at centers like Jackson Laboratory, Drosophila models developed by researchers at University of Edinburgh, and induced pluripotent stem cell (iPSC) lines differentiated into dopaminergic neurons in labs at Kyoto University and Stanford University. Biophysical studies from European Synchrotron Radiation Facility informed models of allosteric regulation and catalytic cysteine accessibility within the RBR domain.

Therapeutic approaches and research developments

Therapeutic strategies range from gene replacement and viral vector delivery evaluated by teams at University of Pennsylvania and biotech firms collaborating with Bill & Melinda Gates Foundation-funded networks, to small molecules enhancing mitophagy pursued by pharmaceutical groups at Novartis, Pfizer, and startups incubated by Cambridge Innovation Center. Cell-replacement approaches using iPSC-derived neurons have advanced in trials run by centers including UCLA Health and Karolinska University Hospital. Ongoing clinical and preclinical research is coordinated through consortia such as Michael J. Fox Foundation and public–private partnerships involving European Medicines Agency and Food and Drug Administration regulatory frameworks.

Category:Human proteins Category:Genes on chromosome 6